Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 1—January 2022
Research

Streptococcus pneumoniae Serotypes Associated with Death, South Africa, 2012–2018

Annelies MüllerComments to Author , Jackie Kleynhans, Linda de Gouveia, Susan Meiring, Cheryl Cohen, Lucy Jane Hathaway1, Anne von Gottberg1, and for GERMS-SA
Author affiliations: University of Bern Graduate School for Cellular and Biomedical Sciences, Bern, Switzerland (A. Müller); University of Bern Institute for Infectious Diseases, Bern (A. Müller, L.J. Hathaway); National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa (J. Kleynhans, L. de Gouveia, S. Meiring, C. Cohen, A. von Gottberg); University of the Witwatersrand, Johannesburg (J. Kleynhans, S. Meiring, C. Cohen, A. von Gottberg); These authors contributed equally to this article.1

Main Article

Figure 2

Number of isolates per serotype in invasive pneumococcal disease patients in South Africa, 2012–2018. A) Total number of isolates; serotype 8 was the most commonly isolated (507, 12%). Black dots indicate most common serotypes in patients <15 years of age; arrowheads indicate most common serotypes in patients >15 years of age. B) Number of isolates per serotype per year of the 4 most common serotypes in the prevaccine era (1, 19A, 3, and 4) (9), the 4 most common in the vaccine era (8, 19A, 12F, and 3), and 6A and 19F. The 7-valent pneumococcal conjugate vaccine was introduced in 2009, 13-valent in 2011.

Figure 2. Number of isolates per serotype in invasive pneumococcal disease patients in South Africa, 2012–2018. A) Total number of isolates; serotype 8 was the most commonly isolated (507, 12%). Black dots indicate most common serotypes in patients <15 years of age; arrowheads indicate most common serotypes in patients >15 years of age. B) Number of isolates per serotype per year of the 4 most common serotypes in the prevaccine era (1, 19A, 3, and 4) (9), the 4 most common in the vaccine era (8, 19A, 12F, and 3), and 6A and 19F. The 7-valent pneumococcal conjugate vaccine was introduced in 2009, 13-valent in 2011.

Main Article

References
  1. Örtqvist  A, Hedlund  J, Kalin  M. Streptococcus pneumoniae: epidemiology, risk factors, and clinical features. Semin Respir Crit Care Med. 2005;26:563–74. DOIPubMedGoogle Scholar
  2. Hurley  D, Griffin  C, Young  M Jr, Scott  DA, Pride  MW, Scully  IL, et al. Safety, tolerability, and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in adults 60 to 64 years of age. Clin Infect Dis. 2021;73:e1489–97. DOIPubMedGoogle Scholar
  3. Rupp  R, Hurley  D, Grayson  S, Li  J, Nolan  K, McFetridge  RD, et al. A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Hum Vaccin Immunother. 2019;15:549–59. DOIPubMedGoogle Scholar
  4. Clarke  E, Bashorun  AO, Okoye  M, Umesi  A, Badjie Hydara  M, Adigweme  I, et al. Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in The Gambia-Results of a phase 1/2 randomized, double-blinded, controlled trial. Vaccine. 2020;38:399–410. DOIPubMedGoogle Scholar
  5. Weinberger  DM, Shapiro  ED. Pneumococcal vaccines for adults: what’s next? Clin Infect Dis. 2020;70:2493–5. DOIPubMedGoogle Scholar
  6. Balsells  E, Guillot  L, Nair  H, Kyaw  MH. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis. PLoS One. 2017;12:e0177113. DOIPubMedGoogle Scholar
  7. Weinberger  DM, Malley  R, Lipsitch  M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011;378:1962–73. DOIPubMedGoogle Scholar
  8. Fleming-Dutra  KE, Conklin  L, Loo  JD, Knoll  MD, Park  DE, Kirk  J, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type nasopharyngeal carriage. Pediatr Infect Dis J. 2014;33(Suppl 2):S152–60. DOIPubMedGoogle Scholar
  9. Cohen  C, Naidoo  N, Meiring  S, de Gouveia  L, von Mollendorf  C, Walaza  S, et al.; GERMS-SA. GERMS-SA. Streptococcus pneumoniae serotypes and mortality in adults and adolescents in South Africa: analysis of national surveillance data, 2003–2008. PLoS One. 2015;10:e0140185. DOIPubMedGoogle Scholar
  10. von Gottberg  A, Cohen  C, de Gouveia  L, Meiring  S, Quan  V, Whitelaw  A, et al. Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: South Africa, 2003-2008. Vaccine. 2013;31:4200–8. DOIPubMedGoogle Scholar
  11. Iroh Tam  PY, Thielen  BK, Obaro  SK, Brearley  AM, Kaizer  AM, Chu  H, et al. Childhood pneumococcal disease in Africa - A systematic review and meta-analysis of incidence, serotype distribution, and antimicrobial susceptibility. Vaccine. 2017;35:1817–27. DOIPubMedGoogle Scholar
  12. Balsells  E, Dagan  R, Yildirim  I, Gounder  PP, Steens  A, Muñoz-Almagro  C, et al. The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: A systematic review and meta-analysis. J Infect. 2018;77:368–78. DOIPubMedGoogle Scholar
  13. Croucher  NJ, Løchen  A, Bentley  SD. Pneumococcal vaccines: host interactions, population dynamics, and design principles. Annu Rev Microbiol. 2018;72:521–49. DOIPubMedGoogle Scholar
  14. Grabenstein  JD, Musey  LK. Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults. Vaccine. 2014;32:2399–405. DOIPubMedGoogle Scholar
  15. Hathaway  LJ, Grandgirard  D, Valente  LG, Täuber  MG, Leib  SL. Streptococcus pneumoniae capsule determines disease severity in experimental pneumococcal meningitis. Open Biol. 2016;6:150269. DOIPubMedGoogle Scholar
  16. Jacques  LC, Panagiotou  S, Baltazar  M, Senghore  M, Khandaker  S, Xu  R, et al. Increased pathogenicity of pneumococcal serotype 1 is driven by rapid autolysis and release of pneumolysin. Nat Commun. 2020;11:1892. DOIPubMedGoogle Scholar
  17. Song  JY, Nahm  MH, Moseley  MA. Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance. J Korean Med Sci. 2013;28:4–15. DOIPubMedGoogle Scholar
  18. Venkateswaran  PS, Stanton  N, Austrian  R. Type variation of strains of Streptococcus pneumoniae in capsular serogroup 15. J Infect Dis. 1983;147:1041–54. DOIPubMedGoogle Scholar
  19. Cohen  C, Naidoo  N, Meiring  S, de Gouveia  L, von Mollendorf  C, Walaza  S, et al.; GERMS-SA. GERMS-SA. Streptococcus pneumoniae serotypes and mortality in adults and adolescents in South Africa: analysis of national surveillance data, 2003–2008. PLoS One. 2015;10:e0140185. DOIPubMedGoogle Scholar
  20. Antonio  M, Hakeem  I, Awine  T, Secka  O, Sankareh  K, Nsekpong  D, et al. Seasonality and outbreak of a predominant Streptococcus pneumoniae serotype 1 clone from The Gambia: expansion of ST217 hypervirulent clonal complex in West Africa. BMC Microbiol. 2008;8:198. DOIPubMedGoogle Scholar
  21. Le Hello  S, Watson  M, Levy  M, Marcon  S, Brown  M, Yvon  JF, et al. Invasive serotype 1 Streptococcus pneumoniae outbreaks in the South Pacific from 2000 to 2007. J Clin Microbiol. 2010;48:2968–71. DOIPubMedGoogle Scholar
  22. Martens  P, Worm  SW, Lundgren  B, Konradsen  HB, Benfield  T. Serotype-specific mortality from invasive Streptococcus pneumoniae disease revisited. BMC Infect Dis. 2004;4:21. DOIPubMedGoogle Scholar
  23. Burgos  J, Falcó  V, Borrego  A, Sordé  R, Larrosa  MN, Martinez  X, et al. Impact of the emergence of non-vaccine pneumococcal serotypes on the clinical presentation and outcome of adults with invasive pneumococcal pneumonia. Clin Microbiol Infect. 2013;19:385–91. DOIPubMedGoogle Scholar
  24. Weinberger  DM, Harboe  ZB, Sanders  EA, Ndiritu  M, Klugman  KP, Rückinger  S, et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis. 2010;51:692–9. DOIPubMedGoogle Scholar
  25. Varon  E, Cohen  R, Béchet  S, Doit  C, Levy  C. Invasive disease potential of pneumococci before and after the 13-valent pneumococcal conjugate vaccine implementation in children. Vaccine. 2015;33:6178–85. DOIPubMedGoogle Scholar
  26. Brueggemann  AB, Peto  TE, Crook  DW, Butler  JC, Kristinsson  KG, Spratt  BG. Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis. 2004;190:1203–11. DOIPubMedGoogle Scholar
  27. Johnson  HL, Deloria-Knoll  M, Levine  OS, Stoszek  SK, Freimanis Hance  L, Reithinger  R, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010;7:e1000348. DOIPubMedGoogle Scholar
  28. du Plessis  M, Allam  M, Tempia  S, Wolter  N, de Gouveia  L, von Mollendorf  C, et al. Phylogenetic analysis of invasive serotype 1 pneumococcus in South Africa, 1989 to 2013. J Clin Microbiol. 2016;54:1326–34. DOIPubMedGoogle Scholar
  29. von Mollendorf  C, Cohen  C, Tempia  S, Meiring  S, de Gouveia  L, Quan  V, et al.; Group for Enteric, Respiratory, and Meningeal Disease Surveillance in South Africa (GERMS-SA). Epidemiology of serotype 1 invasive pneumococcal disease, South Africa, 2003–2013. Emerg Infect Dis. 2016;22:261–70. DOIPubMedGoogle Scholar
  30. Harboe  ZB, Thomsen  RW, Riis  A, Valentiner-Branth  P, Christensen  JJ, Lambertsen  L, et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med. 2009;6:e1000081. DOIPubMedGoogle Scholar
  31. Tan  TQ. Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. Clin Microbiol Rev. 2012;25:409–19. DOIPubMedGoogle Scholar
  32. Løchen  A, Croucher  NJ, Anderson  RM. Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency. Sci Rep. 2020;10:18977. DOIPubMedGoogle Scholar
  33. Cui  YA, Patel  H, O’Neil  WM, Li  S, Saddier  P. Pneumococcal serotype distribution: A snapshot of recent data in pediatric and adult populations around the world. Hum Vaccin Immunother. 2017;13:1–13. DOIPubMedGoogle Scholar
  34. Savinova  T, Brzhozovskaya  E, Shagin  D, Mikhaylova  Y, Shelenkov  A, Yanushevich  Y, et al. A multiple drug-resistant Streptococcus pneumoniae of serotype 15A occurring from serotype 19A by capsular switching. Vaccine. 2020;38:5114–8. DOIPubMedGoogle Scholar
  35. van der Linden  M, Perniciaro  S, Imöhl  M. Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era. BMC Infect Dis. 2015;15:207. DOIPubMedGoogle Scholar
  36. Liyanapathirana  V, Nelson  EA, Ang  I, Subramanian  R, Ma  H, Ip  M. Emergence of serogroup 15 Streptococcus pneumoniae of diverse genetic backgrounds following the introduction of pneumococcal conjugate vaccines in Hong Kong. Diagn Microbiol Infect Dis. 2015;81:66–70. DOIPubMedGoogle Scholar

Main Article

Page created: December 13, 2021
Page updated: December 20, 2021
Page reviewed: December 20, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external